CompletedNCT05311488
Early Detection of Neuropathy in ATTRv
Studying Hereditary amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Pennsylvania
- Principal Investigator
- Chafic Karam, MD, MDUniversity of Pennsylvania
- Intervention
- neurofilament light chain(diagnostic_test)
- Enrollment
- 47 enrolled
- Eligibility
- 30-90 years · All sexes
- Timeline
- 2022 – 2026
Study locations (1)
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
Collaborators
Ionis Pharmaceuticals, Inc. · AstraZeneca
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05311488 on ClinicalTrials.govOther trials for Hereditary amyloidosis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06672237A Phase 3 Study of NTLA-2001 in ATTRv-PNIntellia Therapeutics
- ENROLLING BY INVITATIONNCT07124377Phenotypic Manifestations of Hereditary ATTR AmyloidosisHospital 9 de Julio de Las Breñas
- RECRUITINGNCT06251778NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on TafamidisPaolo Milani
- RECRUITINGPHASE2NCT05758493Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic AmyloidosisOregon Health and Science University